A Phase 1 Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Selgantolimod upon Co-administration with a Representative Proton Pump Inhibitor or H2-Receptor Antagonist in healthy adults
Latest Information Update: 08 Jul 2021
At a glance
- Drugs Selgantolimod (Primary) ; Famotidine; Omeprazole
- Indications Hepatitis B
- Focus Pharmacokinetics
- Sponsors Gilead Sciences
- 07 Jul 2021 Status changed from recruiting to completed.
- 08 Oct 2020 New trial record